While anti-portal hypertensive effects of FXR agonists have been previously observed in rodent models of non-NASH etiology [13,25,26], this is the first experimental study to demonstrate that non-steroidal FXR agonists can reduce portal hypertension in NASH cirrhosis. This evidence concerns the gene NR1H4 and Cirrhosis.